| Level I | Good quality evidence |
Systematic review of RCTs with consistent findings High quality individual RCT |
| Level II |
Limited quality patient orientated evidence |
Systematic review of lower quality studies or studies with inconsistent findings Low quality clinical trial Cohort studies Case-control studies |
| Level III | Other |
Consensus guidelines, extrapolations from bench research, usual practice, opinion, disease-oriented evidence (intermediate or physiologic outcomes only), or case series |
[30] Bisphosphonates, IV (therapeutic grouping): National Department of Health: Affordable Medicines, EDP-Adult Hospital level. Medicine Review: Bisphosphonates, therapeutic class for hypercalcaemia, including primary hyperparathyroidism, September 2017. http://www.health.gov.za/
Bisphosphonates, IV (therapeutic grouping): Ross JR, Saunders Y, Edmonds PM, Patel S, Wonderling D, Normand C, Broadley K. A systematic review of the role of bisphosphonates in metastatic disease. Health Technol Assess. 2004;8(4):1-176. https://www.ncbi.nlm.nih.gov/pubmed/14960258
Zoledronic acid, IV (dosing): The Society for Endocrinology, Metabolism and Diabetes of South Africa Type 2 Diabetes Guidelines Expert Committee. The 2017 SEMDSA Guideline for the Management of Type 2 Diabetes Guideline Committee. JEMDSA 2017; 21(1)(Supplement 1): S1-S196. http://www.jemdsa.co.za/index.php/JEMDSA/article/view/647/937
Zoledronic acid, IV (dosing): South African Medicines Formulary. 12th Edition. Division of Clinical Pharmacology. University of Cape Town, 2016.